CDMO sales and royalties came in strong. Generic API sales have recovered well
from the temporary dip in the previous quarter and are currently back to
historic levels. This resulted in strong margins and a healthy bottom line.
During the quarter, the DSM products have developed well with sales of
EmboCept S going according to plan and manufacturing having begun for both
SmartGel and SmartPan. With two out of three financial targets fulfilled
during Q2, we keep our long-term scenario intact and therefore maintain our
valuation interval.
Aktuellt
SENASTE
